Study S002197

Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02879409
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 150
Start: 2016-11
Primary completion: 2023-10-01
Lead sponsor: Weill Cornell Medical College in Qatar
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG:Metformin; DRUG:Gliclazide; DRUG:Sitagliptin; DRUG:Liraglutide; DRUG:Pioglitazone; DRUG:Dapagliflozin; DRUG:human insulin
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER_GRANT:NPRP: 8-315-3-065; OTHER:14-00058; OTHER:15103/15

Registered primary outcomes

Determination of the variability of HbA1c (by measurement of standard deviation of HbA1c) between the 2 diabetes treatment thresholds [24-30 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.